Synapse - Michael Mauro

Search Within

Michael John Mauro

Results (3)

Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial

Meeting Abstract

Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
Value in Health (2022)

Fulltext@MSK | Save

A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors

Meeting Abstract

Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
Value in Health (2022)

Fulltext@MSK | Save

Imatinib discontinuation and Tki switching patterns in the retrospective and prospective cohorts in simplicity, a study of chronic-phase chronic myeloid leukemia (Cp-Cml) patients (Pts) in routine clinical practice

Meeting Abstract

Zyczynski, T.; Khoury, J.; Goldberg, S.; Mauro, M.; Michallet, M.; Paquette, R.; Foreman, A.; Subar, M.; Turner, M.; Daumont, M. M.; more...
Value in Health (2016)

Fulltext@MSK | Save